Avadel XWPharma partnership secures global rights to valiloxybate, targeting narcolepsy and idiopathic hypersomnia.
• Avadel secures global rights to valiloxybate on October 2023.
• Targets narcolepsy and idiopathic hypersomnia with a sodium-free formulation.
• Enhances patient convenience with once-at-bedtime dosing.
Avadel Pharmaceuticals has entered into a partnership with XWPharma to secure global rights for the development and commercialization of valiloxybate. This agreement, announced in October 2023, focuses on treating narcolepsy and idiopathic hypersomnia. The medication features a once-at-bedtime, sodium-free formulation designed to improve patient convenience and outcomes. Read more about the partnership.
Why it matters
The partnership between Avadel and XWPharma is significant due to the potential impact on patients suffering from sleep disorders. Narcolepsy and idiopathic hypersomnia affect millions worldwide, and current treatments often require multiple doses throughout the day. By offering a once-at-bedtime option, valiloxybate aims to simplify treatment regimens and enhance adherence. Moreover, the sodium-free formulation addresses concerns related to sodium intake, which is crucial for patients with dietary restrictions.
What’s next
Following this agreement, Avadel plans to advance the clinical development of valiloxybate. The company will focus on obtaining regulatory approvals in key markets globally. Additionally, Avadel aims to collaborate with healthcare providers to ensure successful market entry and patient access. For further insights into this development, visit our insights section.